With a strong launch underway for a bladder cancer gene therapy, Ferring Pharmaceuticals is finding the kind of commercial ...

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA ...

ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Countdown Begins to November 18, 2025 PDUFA for Plozasiran Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is developing plozasiran for the ...

After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story ACA premiums set to spike People who buy ...

From innovation in manufacturing to more-flexible regulation and better communication with payers, much needs to happen to ...

Wall Street had a slew of upgrades and downgrades from analysts. Here are some of the major calls for the week: J.P. Morgan ...

PTC Therapeutics faces pivotal FDA decisions for approvals that could potentially transform their long-term revenues. Click ...

Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA), ...

The abrupt exit of the former CBER director raises questions about the FDA’s leadership. For now, newly appointed CDER head George Tidmarsh will take over Prasad’s post.

Sarepta finally gets some good news: A patient death wasn’t its DMD drug’s fault. FDA says the drugmaker can start shipping Elevidys again, but analysts worry it will take time for doctors and ...

Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for its muscular gene therapy soothes immediate concerns about liquidity and ...